Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Type of study
Language
Publication year range
2.
Sangre (Barc) ; 37(6): 465-6, 1992 Dec.
Article in Spanish | MEDLINE | ID: mdl-1293799

ABSTRACT

Philadelphia chromosome-positive chronic myeloid leukaemia (CML) developed three years after the diagnosis of Waldenström macroglobulinemia (WM) in a patient who had received chlorambucil and prednisone during this time. Treatment with busulphan was started and two and a half years later the died in blastic crisis. Six months before the blastic transformation of the leukaemia the amount of IgM, which remains stable (above normal values) along the chronic phase, initiates a decrease, reaching normal values in the phase of acute transformation. CML is a very rare second neoplasia in patients receiving anticancer drugs. The correlation between the decrease of IgM and the blastic crisis is very interesting. We do not find an explanation for this finding although similar observations have been described heralding the appearance of second neoplasias in WM, and one might speculate with a possible role of IgM in the control of chronic phase of the myeloid leukaemia or if the overgrowth of blastic cells could overwhelm the development of lymphoplasmacytoid cells.


Subject(s)
Chlorambucil/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/chemically induced , Neoplasms, Second Primary , Waldenstrom Macroglobulinemia , Busulfan/therapeutic use , Chlorambucil/administration & dosage , Chlorambucil/therapeutic use , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Middle Aged , Neoplasms, Second Primary/drug therapy , Neoplasms, Second Primary/pathology , Prednisone/administration & dosage , Prednisone/therapeutic use , Waldenstrom Macroglobulinemia/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...